Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V205C (rHA) vs V205C (HSA) in Healthy Children
NCT00092404Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2001
- Primary completion
- Jun 2005
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 2, randomised, double-blind trial of M-M-R II in measles, mumps and rubella (2 arms), sponsored by Merck & Co. Primary endpoint: Antibody response rates to measles, mumps, and rubella at 6 weeks. Started Dec 2001; status: completed.
02
Drugs
M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on NCT00092404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092404.